AlloVir (ALVR) Competitors $2.68 -0.01 (-0.37%) As of 07/31/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALVR vs. PDSB, IPSC, PYRGF, RENB, ANL, CALC, PRLD, KALA, CGTX, and NRXPShould you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include PDS Biotechnology (PDSB), Century Therapeutics (IPSC), PyroGenesis Canada (PYRGF), Renovaro (RENB), Adlai Nortye (ANL), CalciMedica (CALC), Prelude Therapeutics (PRLD), KALA BIO (KALA), Cognition Therapeutics (CGTX), and NRx Pharmaceuticals (NRXP). These companies are all part of the "pharmaceutical products" industry. AlloVir vs. Its Competitors PDS Biotechnology Century Therapeutics PyroGenesis Canada Renovaro Adlai Nortye CalciMedica Prelude Therapeutics KALA BIO Cognition Therapeutics NRx Pharmaceuticals AlloVir (NASDAQ:ALVR) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership. Do analysts prefer ALVR or PDSB? PDS Biotechnology has a consensus price target of $9.00, indicating a potential upside of 737.99%. Given PDS Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe PDS Biotechnology is more favorable than AlloVir.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00PDS Biotechnology 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Is ALVR or PDSB more profitable? AlloVir's return on equity of -71.03% beat PDS Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets AlloVirN/A -71.03% -61.27% PDS Biotechnology N/A -150.59%-69.15% Which has more risk and volatility, ALVR or PDSB? AlloVir has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Does the media favor ALVR or PDSB? In the previous week, AlloVir had 1 more articles in the media than PDS Biotechnology. MarketBeat recorded 1 mentions for AlloVir and 0 mentions for PDS Biotechnology. AlloVir's average media sentiment score of 0.67 beat PDS Biotechnology's score of 0.00 indicating that AlloVir is being referred to more favorably in the media. Company Overall Sentiment AlloVir Positive PDS Biotechnology Neutral Do insiders & institutionals have more ownership in ALVR or PDSB? 66.1% of AlloVir shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 32.1% of AlloVir shares are owned by company insiders. Comparatively, 9.2% of PDS Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has better valuation and earnings, ALVR or PDSB? PDS Biotechnology is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlloVirN/AN/A-$190.42M-$20.23-0.13PDS BiotechnologyN/AN/A-$37.61M-$0.94-1.14 SummaryAlloVir and PDS Biotechnology tied by winning 7 of the 14 factors compared between the two stocks. Get AlloVir News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALVR vs. The Competition Export to ExcelMetricAlloVirBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.48M$268.50M$5.45B$9.29BDividend YieldN/AN/A4.71%4.06%P/E Ratio-0.13N/A29.4724.30Price / SalesN/A326.73418.80168.61Price / CashN/A22.4435.8358.21Price / Book0.0910.068.275.54Net Income-$190.42M-$106.40M$3.24B$259.03M7 Day Performance-5.63%-9.44%-3.77%-4.63%1 Month Performance0.37%12.15%5.61%5.86%1 Year Performance-85.43%5.21%22.78%15.16% AlloVir Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALVRAlloVirN/A$2.68-0.4%N/A-84.2%$49.48MN/A-0.13110Upcoming EarningsPDSBPDS Biotechnology1.4574 of 5 stars$1.18flat$9.00+662.7%-69.9%$53.94MN/A-1.2620IPSCCentury Therapeutics3.4258 of 5 stars$0.64+2.3%$4.20+556.3%-75.4%$53.90M$6.59M-2.21170Positive NewsGap DownHigh Trading VolumePYRGFPyroGenesis Canada0.093 of 5 stars$0.29-2.9%N/A-53.4%$53.85M$9.14M-4.7990News CoverageGap UpHigh Trading VolumeRENBRenovaro0.8694 of 5 stars$0.32+2.1%N/A-65.0%$53.17MN/A-0.4120Gap UpHigh Trading VolumeANLAdlai Nortye2.0016 of 5 stars$1.42-1.7%$9.00+536.0%-59.1%$53.14MN/A0.00127Upcoming EarningsCALCCalciMedica2.9602 of 5 stars$3.71-2.4%$16.00+331.3%-26.3%$53.09MN/A-2.3830PRLDPrelude Therapeutics3.123 of 5 stars$0.85-8.4%$4.50+428.1%-87.8%$52.51M$7M-0.50120Positive NewsGap UpHigh Trading VolumeKALAKALA BIO3.7246 of 5 stars$7.93-2.0%$13.00+63.9%+2.9%$52.20M$3.89M-0.9630Upcoming EarningsGap DownCGTXCognition Therapeutics2.0983 of 5 stars$0.72-14.9%$2.83+296.2%-41.4%$52.07MN/A-0.9720Upcoming EarningsShort Interest ↑Gap DownNRXPNRx Pharmaceuticals2.4736 of 5 stars$2.93-2.3%$28.50+872.7%+17.5%$51.87MN/A-1.462 Related Companies and Tools Related Companies PDSB Alternatives IPSC Alternatives PYRGF Alternatives RENB Alternatives ANL Alternatives CALC Alternatives PRLD Alternatives KALA Alternatives CGTX Alternatives NRXP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALVR) was last updated on 8/1/2025 by MarketBeat.com Staff From Our PartnersWall Street Hates This Gold IRA Strategy—Here’s WhyWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!99.8% voted YES on this crypto partnership Kraken—one of the world's biggest crypto exchanges—just picked O...Crypto 101 Media | SponsoredIf you saw this, you'd be scared tooMarkets may look strong—but one veteran analyst warns we’re nearing a financial breaking point. After 40+ y...InvestorPlace | SponsoredWhy “The Prophet” Is Betting Big on This $10 StockAmerica's Biggest Land Grab Is Not Where You Think While the media focuses on coastal cities and farmland.....Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AlloVir With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALVR Stock Alerts